Intrommune

2 known investors

Intrommune Therapeutics develops oral mucosal immunotherapy (OMIT) products that embed food-allergen proteins into a functional toothpaste for daily at-home treatment of food allergies. Its platform targets patients with food allergies, aiming to provide a disease-modifying treatment administered while brushing teeth.